As discussed above, intravenous administration of iron to PAH patients increases exercise endurance capacity, while oral supplementation has little effect due to low intestinal iron absorption in the presence of high levels of hepcidin [13]. The gene discussed is HAMP; the disease is pulmonary arterial hypertension.